Article ID Journal Published Year Pages File Type
5581784 Clinical Lymphoma Myeloma and Leukemia 2017 36 Pages PDF
Abstract
The risks of Afib/Aflutter and all-grade bleeding were significantly higher in the ibrutinib group. These results indicate the need for vigilant monitoring while the patient is receiving ibrutinib therapy, and careful assessment of the risks and benefits of anticoagulation is required.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Preview
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials
Authors
, , , ,